Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

Januvia is one of 10 drugs that was subject to Medicare drug price negotiations, a policy under the Inflation Reduction Act that aims to make costly medications more affordable for older Americans.

Key Takeaways Merck shares fell sharply Tuesday morning after the drugmaker's profits and 2025 outlook fell short of estimates.Revenue and adjusted earnings, however, managed to top expectations.Sales ...

Merck's stock tumbled 8% early Tuesday to lead S&P 500 decliners in the premarket, after the drug company's softer-than-expected guidance for the current year offset better-than-expected ...

She said: “With nutrition, there is no all or nothing. Erectile dysfunction can be triggered by eating spicy food Eating disorders among children doubled in under 10 years Popular fasting diet more ...